Dow Agro CEO retiring as divesture speculation returns
Dow AgroSciences is getting a new chief, the company said Friday. Meanwhile, the CEO of parent company Dow Chemical says Dow Agro could be sold off in a year or two.
Life Science & Biotech
Articles
Top 10 most profitable hospitals around Indianapolis
Based on 2012 data, 23 of 30 hospitals in central Indiana are generating profits from their operations of 10 percent or more. The Indiana Orthopaedic Hospital and St. Vincent's Carmel campus are on top. After that, there are a few surprises.
Can we, please, get a better name than ‘accountable care’?
Health care is going through dramatic change—but is doing so under some of the dullest names possible. So I’m offering a few alternatives that are more to the point. How about, ‘No-more-bankruptcy care’?
Biomet plans $40.5 million upgrade, 150 jobs
Biomet’s project calls for building renovations and adding 3-D printing and optical scanning technology. The Warsaw-based company would also upgrade an incubation center for surgeons interested in introducing a new product, technology or technique.
In one chart: Obamacare exchange has failed to expand coverage in Indiana
For 2014, at least, Obamacare's dreams of expanding individual insurance coverage in Indiana have simply failed. There's no getting around it.
Purdue-based cancer imaging firm lands $15M in funding
OnTarget Laboratories LLC’s technology was developed by Philip Low, a Purdue chemistry professor who also created the technology behind Endocyte Inc.
Republicans needed to make Obamacare work
Obama’s latest delay of Obamacare insurance rules could sabotage the law’s exchanges. The president must be counting on Republican critics, like Indiana Insurance Commissioner Stephen Robertson, to stop him.
Biomet files to sell shares in IPO to pay down debt
Indiana-based Biomet Group Inc., a closely held maker of orthopedic medical devices, had been publicly traded until 2007 when it was acquired by the group of private equity firms.
Health insurance brokers must change to survive
Employees, rather than employers, will soon choose their own health insurers—either through the Obamacare exchanges or through private exchanges. Does that mean health insurance brokers, the people who match up employers with insurers, will no longer be needed?
Dow AgroSciences nears jackpot from genetic engineering
Dow AgroSciences LLC is spending millions of dollars and racking up hundreds of patents as its expands ever deeper in the burgeoning global market for genetically modified crops and pesticides.
Hospital layoffs hardly dented employment growth
Even though the state’s three largest hospital systems–IU Health, St. Vincent Health and Franciscan Alliance–eliminated a combined 2,700 jobs, it created just a blip in the long-term run-up in hospital employment.
Indy hospitals, doctors should start a price war
The choice for health care providers is binary: either limit patient choice through restricted networks or preserve patient choice by making price transparency real and usable. Hospitals and doctors would be better served by the latter.
Life sciences jobs pack 2-for-1 punch
While life sciences companies don’t rack up huge jobs numbers, their relatively high pay means that every job they create is worth two in the rest of the private sector.
What happens if Pence, Sebelius can’t make a deal?
Even if Gov. Mike Pence and Obama’s health secretary can’t come to terms this weekend, there are ideas bouncing around the state legislature that suggest other ways Indiana could expand coverage to low-income Hoosiers.
Lilly drug shows promise as lung cancer treatment
Shares of Eli Lilly and Co. rose as much as 3.8 percent Wednesday morning after the Indianapolis-based drugmaker revealed that an experimental drug boosted overall survival among lung cancer patients in a large trial.
The weightlessness of Obamacare
Rich employer benefits are not always so attractive, sick patients are not always money losers for insurers, and hospitals and doctors are now health care preventers rather than health care providers. This is the bizarre world to which Obamacare has brought us.
Hospitals’ worries about Obamacare plans misplaced
The latest enrollment data from the Obamacare exchanges show that three out of four Hoosiers are purchasing decent coverage—not the super high-deductible plans that concerned hospitals.
Ex-Marcadia execs raise $1.7M to launch drug firm
Fritz French and Richard DiMarchi, the former leaders of Marcadia Biotech, have teamed up to launch the diabetes drug development firm Calibrium LLC.
Generous employer benefits now hurt some workers
Ever since World War 2, when employers started using health benefits to compete for workers, the less employees had to pay toward health insurance premiums the more attractive the benefits. But under Obamacare, this axiom will not always be true.
Deals up, dollars down in 2013 for Indiana life sciences firms
Venture capitalists and angel investors put a combined $31.9 million into 18 life sciences companies last year, with some of the largest amounts going to Nextremity Solutions, hc1.com and FAST BioMedical.